BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15566502)

  • 1. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
    Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
    Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
    J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.
    Dai MS; Wu PF; Lu JJ; Shyu RY; Chao TY
    Support Care Cancer; 2004 Mar; 12(3):191-6. PubMed ID: 15074316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
    Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
    J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
    Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
    Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
    Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
    Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
    Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
    Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
    Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.